{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:49:31Z","timestamp":1790819371353,"version":"4.1.0"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T00:00:00Z","timestamp":1523577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0196007","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T15:01:34Z","timestamp":1523631694000},"page":"e0196007","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":146,"title":["Assessment of costs associated with adverse events in patients with cancer"],"prefix":"10.1371","volume":"13","author":[{"given":"William","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeun Mi","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4867-4739","authenticated-orcid":true,"given":"Martin","family":"Cloutier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolaine","family":"Gauthier-Loiselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Gagnon-Sanschagrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options","volume":"33","author":"LE Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1634\/theoncologist.2016-0177","article-title":"New Frameworks to Assess Value of Cancer Care: Strengths and Limitations","volume":"21","author":"LE Schnipper","year":"2016","journal-title":"Oncologist"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/1471-2407-12-362","article-title":"Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice","volume":"12","author":"D Weycker","year":"2012","journal-title":"BMC Cancer"},{"key":"ref4","first-page":"913848","article-title":"Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer","volume":"2012","author":"CT Pike","year":"2012","journal-title":"Chemother Res Pract"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/13696998.2016.1225577","article-title":"The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States","volume":"20","author":"D Latremouille-Viau","year":"2017","journal-title":"J Med Econ"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1634\/theoncologist.2014-0059","article-title":"Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting","volume":"19","author":"S Hurvitz","year":"2014","journal-title":"Oncologist"},{"key":"ref7","first-page":"203","article-title":"Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States","volume":"9","author":"SP Bilir","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.18553\/jmcp.2015.21.10.863","article-title":"Clinical Impact of Chemotherapy-Related Adverse Events in Patients with Metastatic Breast Cancer in an Integrated Health Care System","volume":"21","author":"N Rashid","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/cncr.20983","article-title":"Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy","volume":"103","author":"V Caggiano","year":"2005","journal-title":"Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/archdermatol.2011.719","article-title":"Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents","volume":"147","author":"JH Borovicka","year":"2011","journal-title":"Arch Dermatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e0124169","DOI":"10.1371\/journal.pone.0124169","article-title":"The Impact of Outpatient Chemotherapy-Related Adverse Events on the Quality of Life of Breast Cancer Patients","volume":"10","author":"T Tachi","year":"2015","journal-title":"PLoS ONE"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1078155212465995","article-title":"Adverse drug events resulting in admission to the intensive care unit in oncology patients: Incidence, characteristics and associated cost","volume":"19","author":"LH Nazer","year":"2013","journal-title":"J Oncol Pharm Pract"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1080\/13696998.2016.1184155","article-title":"Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries","volume":"19","author":"K Vouk","year":"2016","journal-title":"J Med Econ"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.lungcan.2011.04.010","article-title":"Comparison of treatment costs of grade 3\/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain","volume":"74","author":"K Banz","year":"2011","journal-title":"Lung Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/2193-1801-3-259","article-title":"Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens","volume":"3","author":"RN Hansen","year":"2014","journal-title":"Springerplus"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.18553\/jmcp.2015.21.2.158","article-title":"Economic burden associated with adverse events in patients with metastatic melanoma","volume":"21","author":"B Arondekar","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2046-4053-3-47","article-title":"Micro-costing studies in the health and medical literature: a systematic review","volume":"3","author":"X Xu","year":"2014","journal-title":"Syst Rev"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1097\/MLR.0b013e3181a75a7f","article-title":"Assigning Resources to Health Care Use for Health Services Research: Options and Consequences","volume":"47","author":"PA Fishman","year":"2009","journal-title":"Med Care"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/MLR.0b013e31819bc064","article-title":"Micro-Costing Quantity Data Collection Methods","volume":"47","author":"KD Frick","year":"2009","journal-title":"Med Care"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/hec.1363","article-title":"The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches","volume":"18","author":"FM Clement Nee Shrive","year":"2009","journal-title":"Health Econ"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1586\/14737167.2.1.29","article-title":"Microcosting versus DRGs in the provision of cost estimates for use in pharmacoeconomic evaluation","volume":"2","author":"A Heerey","year":"2002","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mdm525","article-title":"Cost of neutropenic complications of chemotherapy","volume":"19","author":"D Weycker","year":"2008","journal-title":"Ann Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the Cost of Cancer Care in the United States: 2010\u20132020","volume":"103","author":"AB Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"ref24","unstructured":"ICER. Overview of the ICER value assessment framework and update for 2017\u20132019. Available from: https:\/\/icer-review.org\/final-vaf-2017-2019\/<\/ext-link>. Cited June 2017."},{"key":"ref25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget Impact Analysis\u2014Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force","volume":"17","author":"SD Sullivan","year":"2014","journal-title":"Value Health"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0196007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T23:01:46Z","timestamp":1540249306000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0196007"}},"subtitle":[],"editor":[{"given":"Ramon Andrade","family":"De Mello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,4,13]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0196007","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,13]]}}}